<?xml version='1.0' encoding='utf-8'?>
<document id="26842595"><sentence text="In Vitro-In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition." /><sentence text="Relative expression factors (REFs) are used to scale in vitro transporter kinetic data via in vitro-in vivo extrapolation linked to physiologically based pharmacokinetic (IVIVE-PBPK) models to clinical observations" /><sentence text=" Primarily two techniques to quantify transporter protein expression are available, immunoblotting and liquid chromatography-tandem mass spectrometry" /><sentence text=" Literature-collated REFs ranged from 0" /><sentence text="4 to 5" /><sentence text="1 and 1" /><sentence text="1 to 90 for intestinal P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), respectively" /><sentence text=" The impact of using human jejunum-Caco-2 REFs for P-gp (REFiP-gp) and BCRP (REFiBCRP), generated from the same samples and using different proteomic methodologies from independent laboratories, on PBPK outcomes was assessed" /><sentence text=" A 5-fold decrease in REFiP-gp for a single oral dose of digoxin resulted in a 1"><entity charOffset="57-64" id="DDI-PubMed.26842595.s9.e0" text="digoxin" /></sentence><sentence text="19- and 1" /><sentence text="31-fold higher plasma area under the curve and Cmax, respectively" /><sentence text=" All generated REFiP-gp values led to simulated digoxin Cmax values within observed ranges; however, combining kinetic data generated from a different laboratory with the 5-fold lower REFiP-gp could not recover a digoxin-rifampicin drug-drug interaction, emphasizing the necessity to obtain transporter-specific kinetic estimates and REFs from the same in vitro system"><entity charOffset="213-220" id="DDI-PubMed.26842595.s12.e0" text="digoxin" /><entity charOffset="221-231" id="DDI-PubMed.26842595.s12.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.26842595.s12.e0" e2="DDI-PubMed.26842595.s12.e0" /><pair ddi="false" e1="DDI-PubMed.26842595.s12.e0" e2="DDI-PubMed.26842595.s12.e1" /></sentence><sentence text=" For a theoretical BCRP compound, with absorption taking place primarily in the jejunum, a decrease in the REFiBCRP from 2" /><sentence text="22 (University of Manchester) to 1" /><sentence text="11 (Bertin Pharma) promoted proximal intestinal absorption while delaying tmax 1" /><sentence text="44-fold" /><sentence text=" Laboratory-specific differences in REF may lead to different IVIVE-PBPK outcomes" /><sentence text=" To understand the mechanisms underlying projected pharmacokinetic liabilities, it is important to assess the potential impact of bias on the generation of REFs on an interindividual basis within a target population" /><sentence text=" " /></document>